Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus (AAV) vector-based gene therapy designed to treat Hemophilia B. It delivers a functional copy of the human *F9* gene to liver cells, enabling sustained endogenous production of Factor IX (FIX) to reduce the frequency of bleeding episodes.
## Primary Indications
Treatment of adults (≥18 years) with moderate to severe Hemophilia B who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.
## Adult Dosing
* **Dose:** $5 \times 10^{11}$ vector genomes (vg) per kg of body weight.
* **Administration:** Single-dose, slow intravenous infusion.
## Pediatric Dosing
* **Safety and efficacy:** Not established in pediatric patients (<18 years).
## Dose Adjustments
* **Hepatic impairment:** Not formally studied; use caution in patients with preexisting liver disease.
* **Renal impairment:** No dosage adjustments provided.
* **Administration:** If an infusion reaction occurs, the rate may be slowed or interrupted; resume at a slower rate once symptoms resolve.
## Contraindications
* None listed in current FDA labeling, but generally contraindicated in patients with active, severe infections (acute or chronic) or advanced hepatic fibrosis/cirrhosis.
## Adverse Effects
* **Common:** Elevated transaminases (ALT/AST), infusion-related reactions (nausea, fatigue, headache, fever), and increased Factor IX activity levels.
* **Serious:** Potential for hepatotoxicity secondary to immune-mediated clearance of gene-transduced cells; malignancy (theoretical risk related to viral vector integration).
## Key Drug Interactions
* **Immunosuppressants:** Corticosteroids (e.g., prednisone or equivalent) are required post-infusion to manage potential immune response to the AAV vector.
* **Hepatotoxic agents:** Use with caution, as liver enzyme monitoring is critical for identifying potential loss of therapeutic efficacy.
## Monitoring
* **Liver Enzymes:** Monitor ALT/AST weekly for at least the first 3 months post-infusion to assess for asymptomatic hepatitis and potential loss of Factor IX transgene expression.
* **Factor IX Levels:** Monitor FIX activity levels to assess response and potential toxicity.
* **Clinical Bleeding:** Monitor for breakthrough bleeding events, especially during the tapering of prophylactic FIX replacement.
## Clinical Pearls
* **Corticosteroid Taper:** A tapering course of corticosteroids is mandatory to manage immune responses; failure to adhere may result in loss of efficacy.
* **Baseline Status:** Assess patients for pre-existing AAV antibodies (anti-AAVRh74 antibodies) prior to infusion; presence may preclude treatment.
* **Irreversibility:** As a one-time gene therapy, this treatment is non-repeatable. Ensure patient understands the permanent nature of the infusion.
* **Efficacy:** Reductions in annualized bleeding rates (ABR) are typically realized within weeks of infusion.
***
*Disclaimer: This information is for educational purposes only and does not supersede institutional protocols or the FDA-approved prescribing information. Always verify dosing and safety guidelines via the current manufacturer's package insert or official clinical drug database prior to prescribing or administration.*
